RLYB
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Rallybio and Candid Therapeutics entered into a merger agreementMar 2, 2026
- Rallybio reported positive Phase 1 data showing complete and sustained inhibition of terminal complement with RLYB116Feb 17, 2026
- Rallybio completes dosing of first cohort in RLYB116 Phase 1 confirmatory pharmacokinetic/pharmacodynamic studySep 25, 2025
- Recursion acquires full rights to REV102, a potential first-in-class oral ENPP1 inhibitor for hypophosphatasiaJul 9, 2025
- Rallybio begins dosing in Phase 1 PK/PD study of RLYB116Jun 12, 2025